WuXi AppTec Reports Strong Third-Quarter 2021 Results
Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract...
Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract...
營業收入59.85億元,同比增長30.6%歸母淨利潤8.87億元,同比增長36.2%稀釋每股收益0.30元,同比增長30.4%經調整 Non-IFRS歸母淨利潤13.58億元,同比增長37.8%經調整Non-IFRS稀釋每股收益0.46元,...